GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Transgene Biotek Ltd

Transgene Biotek Q2 FY27: Revenue at Rs. 6.00 Lakhs, Net Loss Rs. 34.53 Lakhs

RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 13 Nov 2026, 01:19 PM IST  ·  BSE ID: 1d4e0823-ae30-4e72-8ea1-93e95d021a68
View Original BSE Filing (PDF)
💡
In Simple Terms
Transgene Biotek announced its quarterly financial results, showing Rs. 6.00 Lakhs in sales and a net loss of Rs. 34.53 Lakhs.
🤖 AI Summary
  • Transgene Biotek's Q2 FY27 revenue from operations reached Rs. 6.00 Lakhs for the quarter ended September 30, 2026.
  • The company reported a standalone net loss of Rs. 34.53 Lakhs for the quarter ended September 30, 2026.
  • Standalone total expenses for Q2 FY27 stood at Rs. 40.53 Lakhs, including Rs. 28.95 Lakhs in finance costs.
  • Dr. K. Koteswara Rao was re-appointed as Chairman and Managing Director for one year, effective November 13, 2026.
  • The 36th Annual General Meeting for FY26 is scheduled for December 30, 2026, via video conferencing.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Quarter Ended 30-09-2026)
6.00 Lakhs
13.64%
Profit for the year (Quarter Ended 30-09-2026)
-34.53 Lakhs
Basic EPS (Quarter Ended 30-09-2026)
-0.05 Rs.
0.00%
Total income (Year to date 30-09-2026)
12.00 Lakhs
17.30%
Profit for the year (Year to date 30-09-2026)
-73.43 Lakhs
10.68%
🏢 How This Affects the Company
📈
Business Impact
The consistent revenue from operations at Rs. 6.00 Lakhs for the quarter signals a stable, albeit low, operational activity level for the reported period. The reappointment of the Chairman and Managing Director provides continuity in leadership.
💰
Financial Impact
The net loss of Rs. 34.53 Lakhs for the quarter and Rs. 73.43 Lakhs for the half-year reflects ongoing negative profitability. Finance costs of Rs. 28.95 Lakhs represent a significant portion of expenses, impacting overall financial performance.
⚠️
Risk Impact
Ongoing legal matters noted in the financial results, such as appeals to the Securities Appellate Tribunal and proceedings with NCLT and Enforcement Directorate, indicate continued legal and regulatory risks for the company.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are advised to review the Unaudited Financial Results and the details of the 36th Annual General Meeting.
👤
Who Is Affected
All shareholders are affected by the financial performance, specifically the net loss of Rs. 34.53 Lakhs. Shareholders are also invited to the 36th AGM on December 30, 2026.
🔍
Management Signal
The re-appointment of the Chairman and Managing Director indicates a commitment to continuity in the company's existing leadership and strategic direction.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
36th Annual General Meeting on December 30, 2026 — shareholder approval for re-appointment of CMD.
Outcome of Securities Appellate Tribunal hearings — follow up on pending legal matters.
NCLT Hyderabad bench proceedings — monitor developments on outstanding interest claims.
HIGH RISK Persistent net losses, significant finance costs, and multiple pending legal challenges contribute to a high-risk profile.
💡 Investor Takeaway
Transgene Biotek reported a standalone net loss of Rs. 34.53 Lakhs for Q2 FY27 on revenue of Rs. 6.00 Lakhs. Half-year revenue increased to Rs. 12.00 Lakhs from Rs. 10.23 Lakhs YoY. The Board approved the re-appointment of Dr. K. Koteswara Rao as CMD.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from operations increased to Rs. 12.00 Lakhs for the half-year ended September 30, 2026, from Rs. 10.23 Lakhs in the prior half-year.
  • The re-appointment of Dr. K. Koteswara Rao as Chairman and Managing Director provides leadership continuity for one year.

⚠️ Concerns

  • Transgene Biotek reported a standalone net loss of Rs. 34.53 Lakhs for Q2 FY27 and Rs. 73.43 Lakhs for the half-year ended September 30, 2026.
  • Finance costs amounted to Rs. 28.95 Lakhs for the quarter and Rs. 57.90 Lakhs for the half-year, contributing significantly to total expenses.
❓ Frequently Asked Questions
What was Transgene Biotek's revenue from operations in Q2 FY27?
Transgene Biotek reported revenue from operations of Rs. 6.00 Lakhs for the quarter ended September 30, 2026.
What was Transgene Biotek's net profit/loss for Q2 FY27?
The company recorded a standalone net loss of Rs. 34.53 Lakhs for the quarter ended September 30, 2026.
Who was re-appointed as Chairman and Managing Director of Transgene Biotek?
Dr. K. Koteswara Rao (DIN: 07167872) was re-appointed as Chairman and Managing Director for a period of one year, effective November 13, 2026.
When is Transgene Biotek's 36th Annual General Meeting scheduled?
The 36th Annual General Meeting of Transgene Biotek Ltd is scheduled for Wednesday, December 30, 2026, at 11:00 A.M. (IST).
What were the finance costs for Transgene Biotek in Q2 FY27?
Transgene Biotek's finance costs for the quarter ended September 30, 2026, were Rs. 28.95 Lakhs, contributing to total expenses of Rs. 40.53 Lakhs.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.